EicOsis Human Health is on track to initiate a first-in-human Phase 1a clinical trial in the third quarter of 2019 with its novel, non-opioid analgesic compound, EC5026.
EicOsis Human Health is on track to initiate a first-in-human Phase 1a clinical trial in the third quarter of 2019 with its novel, non-opioid analgesic compound, EC5026. EC5026 was selected for support by the NIH’s Blueprint Neurotherapeutics program in 2016 because of novel mechanism of action (inhibition of an intracellular enzyme called soluble epoxide hydrolase) and its high efficacy in nonclinical studies of inflammatory and neuropathic pain with no apparent abuse liability.
EicOsis completed a pre-IND meeting with the FDA’s Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) on April 22, 2019. The conclusion was that the FDA welcomed submission of a full Investigational New Drug (IND) application in June. After discussing all of the questions in EicOsis’s briefing book, Dr. Bruce Hammock, CEO of EicOsis, had an opportunity to tell the FDA about a 500 kg thoroughbred horse with severely painful equine laminitis that was treated successfully with a soluble epoxide hydrolase inhibitor at the UC Davis Veterinary School. The horse had previously been unresponsive to all available medical and non-medical therapies for treating its pain. Several other horses with equine laminitis that were unresponsive to standard-of-care treatment have achieved similar pain relief when treated with a soluble epoxide hydrolase inhibitor at UC Davis. The FDA appeared to be encouraged to hear about the potential translation of analgesic efficacy in large animals with naturally-occurring pain to humans.
In an article entitled, “UC Davis researcher will test non-addictive drug that could lead to a new way to treat pain,” Cathie Andersen, a reporter from the Sacramento Bee newspaper, posted a highly informative story about EicOsis and the discovery of soluble epoxide hydrolase inhibitors in the April 30, 2019, print edition. The April 29 online version is available to read free of charge at https://www.sacbee.com/news/local/health-and-medicine/article229700594.html.
About EicOsis
EicOsis is a privately held company developing a first-in-class therapy of a once daily, oral treatment for neuropathic and inflammatory pain in humans and companion animals. The technology for the lead compounds was developed at the University of California Davis by EicOsis CEO and UC professor, Dr. Bruce Hammock and licensed exclusively to EicOsis from the University of California, Davis. EicOsis has a strong patent position with both method-of-use and composition of matter patents.
EicOsis research reported has been supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number UH2NS094258 and SBIR Award number R44ES025598.
Contact:
Cindy McReynolds
(530) 338-0070
cbmcreynolds@eicosis.com
